GERATHERM MEDICAL AG (GME.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:GME - DE0005495626 - Common Stock
2.88 EUR
-0.01 (-0.35%)
We assign a fundamental rating of 5 out of 10 to GME. GME was compared to 65 industry peers in the Health Care Equipment & Supplies industry. GME is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. GME is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year GME was profitable.
GME had a positive operating cash flow in the past year.
Each year in the past 5 years GME has been profitable.
GME had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 2.56%, GME is in line with its industry, outperforming 43.55% of the companies in the same industry.
GME has a Return On Equity (3.39%) which is in line with its industry peers.
GME has a Return On Invested Capital (4.77%) which is comparable to the rest of the industry.
Measured over the past 3 years, the Average Return On Invested Capital for GME is below the industry average of 10.04%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.56% | ||
| ROE | 3.39% | ||
| ROIC | 4.77% |
ROA(3y)2.74%
ROA(5y)2.85%
ROE(3y)4.3%
ROE(5y)4.73%
ROIC(3y)5.4%
ROIC(5y)5.44%
1.3 Margins
The Profit Margin of GME (5.04%) is comparable to the rest of the industry.
GME's Profit Margin has improved in the last couple of years.
GME has a Operating Margin (10.70%) which is comparable to the rest of the industry.
GME's Operating Margin has improved in the last couple of years.
With a Gross Margin value of 45.35%, GME is not doing good in the industry: 69.35% of the companies in the same industry are doing better.
GME's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.7% | ||
| PM (TTM) | 5.04% | ||
| GM | 45.35% |
OM growth 3Y34.1%
OM growth 5Y23.14%
PM growth 3Y114.71%
PM growth 5Y12.9%
GM growth 3Y-12.69%
GM growth 5Y-8.03%
2. Health
2.1 Basic Checks
GME has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
GME has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for GME has been increased compared to 5 years ago.
The debt/assets ratio for GME has been reduced compared to a year ago.
2.2 Solvency
GME has an Altman-Z score of 2.62. This is not the best score and indicates that GME is in the grey zone with still only limited risk for bankruptcy at the moment.
GME has a Altman-Z score (2.62) which is in line with its industry peers.
There is no outstanding debt for GME. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.27 | ||
| Altman-Z | 2.62 |
ROIC/WACC0.79
WACC6%
2.3 Liquidity
GME has a Current Ratio of 3.04. This indicates that GME is financially healthy and has no problem in meeting its short term obligations.
GME's Current ratio of 3.04 is amongst the best of the industry. GME outperforms 80.65% of its industry peers.
A Quick Ratio of 2.35 indicates that GME has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.35, GME belongs to the top of the industry, outperforming 83.87% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.04 | ||
| Quick Ratio | 2.35 |
3. Growth
3.1 Past
GME shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -37.95%.
Measured over the past 5 years, GME shows a small growth in Earnings Per Share. The EPS has been growing by 3.45% on average per year.
Looking at the last year, GME shows a very negative growth in Revenue. The Revenue has decreased by -33.29% in the last year.
Measured over the past years, GME shows a decrease in Revenue. The Revenue has been decreasing by -6.77% on average per year.
EPS 1Y (TTM)-37.95%
EPS 3Y86.77%
EPS 5Y3.45%
EPS Q2Q%84.62%
Revenue 1Y (TTM)-33.29%
Revenue growth 3Y-16.42%
Revenue growth 5Y-6.77%
Sales Q2Q%-3.99%
3.2 Future
The Earnings Per Share is expected to grow by 30.06% on average over the next years. This is a very strong growth
The Revenue is expected to decrease by -0.56% on average over the next years.
EPS Next Y-120%
EPS Next 2Y9.54%
EPS Next 3Y30.06%
EPS Next 5YN/A
Revenue Next Year-12.36%
Revenue Next 2Y-3.72%
Revenue Next 3Y-0.56%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
GME is valuated rather expensively with a Price/Earnings ratio of 22.15.
Compared to the rest of the industry, the Price/Earnings ratio of GME indicates a somewhat cheap valuation: GME is cheaper than 77.42% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.60. GME is around the same levels.
The Price/Forward Earnings ratio is 47.52, which means the current valuation is very expensive for GME.
Based on the Price/Forward Earnings ratio, GME is valued a bit more expensive than 69.35% of the companies in the same industry.
GME's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.23.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.15 | ||
| Fwd PE | 47.52 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GME indicates a rather cheap valuation: GME is cheaper than 100.00% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, GME is valued cheaply inside the industry as 98.39% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.57 | ||
| EV/EBITDA | 2.21 |
4.3 Compensation for Growth
A more expensive valuation may be justified as GME's earnings are expected to grow with 30.06% in the coming years.
PEG (NY)N/A
PEG (5Y)6.43
EPS Next 2Y9.54%
EPS Next 3Y30.06%
5. Dividend
5.1 Amount
GME has a Yearly Dividend Yield of 3.46%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 0.98, GME pays a better dividend. On top of this GME pays more dividend than 91.94% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 1.94, GME pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.46% |
5.2 History
The dividend of GME decreases each year by -24.21%.
Dividend Growth(5Y)-24.21%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
76.72% of the earnings are spent on dividend by GME. This is not a sustainable payout ratio.
DP76.72%
EPS Next 2Y9.54%
EPS Next 3Y30.06%
FRA:GME (1/2/2026, 7:00:00 PM)
2.88
-0.01 (-0.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners0.14%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap15.58M
Revenue(TTM)13.98M
Net Income(TTM)705.20K
Analysts80
Price Target6.12 (112.5%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.46% |
Yearly Dividend0.1
Dividend Growth(5Y)-24.21%
DP76.72%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.15 | ||
| Fwd PE | 47.52 | ||
| P/S | 1.11 | ||
| P/FCF | 7.57 | ||
| P/OCF | 6.51 | ||
| P/B | 0.75 | ||
| P/tB | 0.81 | ||
| EV/EBITDA | 2.21 |
EPS(TTM)0.13
EY4.51%
EPS(NY)0.06
Fwd EY2.1%
FCF(TTM)0.38
FCFY13.2%
OCF(TTM)0.44
OCFY15.37%
SpS2.58
BVpS3.85
TBVpS3.54
PEG (NY)N/A
PEG (5Y)6.43
Graham Number3.36
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.56% | ||
| ROE | 3.39% | ||
| ROCE | 6.9% | ||
| ROIC | 4.77% | ||
| ROICexc | 8.56% | ||
| ROICexgc | 9.92% | ||
| OM | 10.7% | ||
| PM (TTM) | 5.04% | ||
| GM | 45.35% | ||
| FCFM | 14.71% |
ROA(3y)2.74%
ROA(5y)2.85%
ROE(3y)4.3%
ROE(5y)4.73%
ROIC(3y)5.4%
ROIC(5y)5.44%
ROICexc(3y)7.14%
ROICexc(5y)8.66%
ROICexgc(3y)8.81%
ROICexgc(5y)10.98%
ROCE(3y)7.81%
ROCE(5y)7.88%
ROICexgc growth 3Y2.27%
ROICexgc growth 5Y6.75%
ROICexc growth 3Y7.82%
ROICexc growth 5Y8.18%
OM growth 3Y34.1%
OM growth 5Y23.14%
PM growth 3Y114.71%
PM growth 5Y12.9%
GM growth 3Y-12.69%
GM growth 5Y-8.03%
F-Score4
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.27 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 22.42% | ||
| Cap/Sales | 2.41% | ||
| Interest Coverage | 20.21 | ||
| Cash Conversion | 79.84% | ||
| Profit Quality | 291.69% | ||
| Current Ratio | 3.04 | ||
| Quick Ratio | 2.35 | ||
| Altman-Z | 2.62 |
F-Score4
WACC6%
ROIC/WACC0.79
Cap/Depr(3y)105.18%
Cap/Depr(5y)120.77%
Cap/Sales(3y)7.67%
Cap/Sales(5y)7.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.95%
EPS 3Y86.77%
EPS 5Y3.45%
EPS Q2Q%84.62%
EPS Next Y-120%
EPS Next 2Y9.54%
EPS Next 3Y30.06%
EPS Next 5YN/A
Revenue 1Y (TTM)-33.29%
Revenue growth 3Y-16.42%
Revenue growth 5Y-6.77%
Sales Q2Q%-3.99%
Revenue Next Year-12.36%
Revenue Next 2Y-3.72%
Revenue Next 3Y-0.56%
Revenue Next 5YN/A
EBIT growth 1Y-44.18%
EBIT growth 3Y12.09%
EBIT growth 5Y14.8%
EBIT Next Year300%
EBIT Next 3Y71%
EBIT Next 5Y42.79%
FCF growth 1Y112.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.95%
OCF growth 3Y16.98%
OCF growth 5Y-0.95%
GERATHERM MEDICAL AG / GME.DE FAQ
What is the fundamental rating for GME stock?
ChartMill assigns a fundamental rating of 5 / 10 to GME.DE.
Can you provide the valuation status for GERATHERM MEDICAL AG?
ChartMill assigns a valuation rating of 4 / 10 to GERATHERM MEDICAL AG (GME.DE). This can be considered as Fairly Valued.
What is the profitability of GME stock?
GERATHERM MEDICAL AG (GME.DE) has a profitability rating of 4 / 10.
Can you provide the financial health for GME stock?
The financial health rating of GERATHERM MEDICAL AG (GME.DE) is 8 / 10.
What is the expected EPS growth for GERATHERM MEDICAL AG (GME.DE) stock?
The Earnings per Share (EPS) of GERATHERM MEDICAL AG (GME.DE) is expected to decline by -120% in the next year.